Search Result

Results for "

onset

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Adrenergic Receptor (7) Amine N-methyltransferase (1) AMPK (1) Amyloid-β (2) Androgen Receptor (1) Antibiotic (2) Antifolate (1) Apoptosis (11) Autophagy (9) Bacterial (4) Bcl-2 Family (1) Biochemical Assay Reagents (2) Calcium Channel (1) CDK (1) CRAC Channel (1) Deubiquitinase (2) Dipeptidyl Peptidase (1) DNA/RNA Synthesis (6) Dopamine Receptor (4) Drug Derivative (4) Drug Intermediate (1) Drug Metabolite (1) Endogenous Metabolite (19) FOXO (1) GABA Receptor (5) GCGR (1) GLP Receptor (1) Glucocorticoid Receptor (1) Glycosidase (2) GSK-3 (1) Histone Demethylase (7) Histone Methyltransferase (1) HIV (1) IAP (1) IFNAR (1) iGluR (1) Insulin Receptor (1) Isotope-Labeled Compounds (9) Liposome (2) LPL Receptor (1) mAChR (1) MDM-2/p53 (1) Melatonin Receptor (5) Motilin Receptor (2) nAChR (1) Neurokinin Receptor (1) NF-κB (1) NOD-like Receptor (NLR) (1) Orphan Nuclear Receptor (1) Parasite (2) PD-1/PD-L1 (1) PERK (1) Phosphatase (1) Photosensitizer (3) Platelet-activating Factor Receptor (PAFR) (1) Potassium Channel (3) PPAR (1) Prostaglandin Receptor (9) Proton Pump (1) Reactive Oxygen Species (ROS) (4) Reference Standards (12) RIP kinase (1) ROCK (2) SARS-CoV (1) Ser/Thr Kinase (1) Ser/Thr Protease (1) Serotonin Transporter (1) Small Interfering RNA (siRNA) (1) Sodium Channel (2) STING (2) Tau Protein (1) TGF-β Receptor (1) Thrombin (2) TREM receptor (1) Virus Protease (2) Wee1 (1) YAP (2) α-synuclein (1)
By Research Areas:	Cancer (16) Cardiovascular Disease (7) Endocrinology (13) Infection (9) Inflammation/Immunology (14) Metabolic Disease (16) Neurological Disease (42)
Click Chemistry:	Alkynes (2)
Oligonucleotides:	Pegylated Lipids (1) Phospholipids (1)

108

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12956

Dinoprost Maximum Cited Publications 9 Publications Verification Prostaglandin F2α; PGF2α	Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis	Endocrinology
Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour .

HY-A0014

Ramelteon 10+ Cited Publications TAK-375	Melatonin Receptor	Neurological Disease Endocrinology Cancer
Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation .

HY-168374

DSPE-PEG2000-Mannose 1 Publications Verification	Biochemical Assay Reagents Liposome Small Interfering RNA (siRNA)	Cancer
DSPE-PEG 2000-Mannose is a mannose-containing lipid. DSPE-PEG 2000-Mannose is used to prepare mannose-conjugated Liposome (Man-lipo) for siRNA delivery. Mannose-modified liposomes encapsulating IDO siRNA (Man-lipo-siIDO) preferentially knock down IDO expression in the draining lymph nodes and spleens of melanoma-bearing mice. Man-lipo-siIDO delays the onset time of melanoma and reduces tumor volume .

HY-B0481

Miglitol 2 Publications Verification BAY1099; BAY-m1099	Glycosidase AMPK Reactive Oxygen Species (ROS)	Metabolic Disease
Miglitol (BAY-m1099) is an orally active antidiabetic compound that inhibits the breakdown of glycoconjugates into glucose. Miglitol inhibits glycoside hydrolase enzymes called α-glucosidases. Miglitol inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase. Dietary supplementation with Miglitol from pre-onset stage in OLETF rats delays the onset and development of diabetes and preserves the insulin secretory function of pancreatic islets .

HY-108786

Asfotase alfa ENB-0040	Phosphatase	Metabolic Disease
Asfotase alfa (ENB-0040) is a bone-targeted genetically engineered glycoprotein. Asfotase alfa increases the survival rate, bone mineralization and bone length and prevents mineralization defects of the feet, rib cage, lower limbs, jaw bones in Akp2 ^/ knockout mice. Asfotase alfa can be used for the research of perinatal, infantile, and juvenile-onset hypophosphatasia (HPP) .

HY-14905

Uridine triacetate Tri-O-acetyl uridine	Drug Derivative	Neurological Disease
Uridine triacetate (Tri-O-acetyl uridine) is an orally active proagent of Uridine (HY-B1449). Uridine triacetate is quickly absorbed in the gut, and is rapidly deacetylated in the circulation to yield free uridine. Uridine triacetate is used for the research of 5-fluorouracil (5-FU) and capecitabine toxicity, or early-onset cardiac or central nervous system (CNS) .

HY-B0546

Procaine 2 Publications Verification	Histone Demethylase DNA/RNA Synthesis Bacterial	Neurological Disease Cancer
Procaine is a DNA-demethylating agent. Procaine acts through multiple targets and has a slow onset and a short duration of action .

HY-135484

NDSB-195	Biochemical Assay Reagents	Metabolic Disease
NDSB-195 is protein stabilizer that enhances the dynamics of the β4-α2 loop of ubiquitin. NDSB-195 stabilizes Saccharomyces cerevisiae ubiquitin against guanidium chloride denaturation, increasing the onset temperature of heat denaturation in the presence of the denaturant .

HY-148417

ZZL-7	Serotonin Transporter	Neurological Disease
ZZL-7 is a fast-onset antidepressant agent. ZZL-7 works by disrupting the interaction between the serotonin transporter (SERT) and neuronal nitric oxide synthase (nNOS) in the dorsal raphe nucleus (DRN). ZZL-7 can cross the blood-brain barrier readily. ZZL-7 can be used for the research of major depressive disorder (MDD) .

HY-P990043

Iluzanebart VGL101	Ser/Thr Kinase TREM receptor	Inflammation/Immunology
Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP) .

HY-B0546A

Procaine hydrochloride 2 Publications Verification	Histone Demethylase DNA/RNA Synthesis Bacterial	Neurological Disease Cancer
Procaine hydrochloride is a DNA-demethylating agent. Procaine hydrochloride acts through multiple targets and has a slow onset and a short duration of action .

HY-10787

Ximelagatran 1 Publications Verification H 376/95	Thrombin	Cardiovascular Disease
Ximelagatran (H 376/95) is an orally active thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcokinetics and pharmacodynamics .

HY-109555

Insulin glulisine HMR 1964	Insulin Receptor	Metabolic Disease Inflammation/Immunology
Insulin glulisine (HMR 1964) is a rapid-acting insulin analog whose pharmacokinetic and pharmacodynamic properties mimic physiological insulin secretion in humans, with a rapid onset of action. Insulin glulisine controls hyperglycemia. Insulin glulisine is applicable to research related to type 1 diabetes and type 2 diabetes .

HY-B1470

Azaperone R-1929	Dopamine Receptor Adrenergic Receptor	Neurological Disease
Azaperone is an antagonist of dopamine D2 receptor (Dopamine D2 Receptor) and α-adrenergic receptor (AR). Azaperone reduces vasomotor tone, mean arterial pressure, hematocrit, hemoglobin concentration, and etorphine-induced duration; induces transient tachycardia followed by bradycardia, splenic uptake of red blood cells, and sedation; alters animal behaviors; and produces sedation with distinct onset and duration in foals. Azaperone is used for sedation and tranquilization in various animals to reduce stress and aggressive behaviors, and serves as a preanesthetic agent .

HY-108882B

DNase I RNase & Protease free Maximum Cited Publications 29 Publications Verification	DNA/RNA Synthesis	Inflammation/Immunology
DNase I is an enzyme that degrades DNA. DNase I is mainly produced by digestive system organs, such as the pancreas and parotid gland. Three types of DNase I are known in mammals: pancreatic type, parotid type, and pancreatico-parotid type. DNase I plays a key role in the cleavage of extracellular DNA, and is critical for limiting inflammatory responses and maintaining homeostasis. DNase I is responsible for digesting extracellular nucleoproteins, which may be essential for preventing autoimmune responses. Decreased DNase I activity may be associated with the onset and progression of systemic lupus erythematosus (SLE). DNase I (RNase & Protease free) is a molecular biology-grade DNase I purified by chromatography to remove RNase and protease .

HY-Y0378

D-Leucine (R)-Leucine	Endogenous Metabolite	Neurological Disease
D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .

HY-12956A

Dinoprost tromethamine salt Maximum Cited Publications 9 Publications Verification Prostaglandin F2α tromethamine salt; PGF2α THAM; Prostaglandin F2α THAM	Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis	Endocrinology
Dinoprost tromethamine salt (Prostaglandin F2α tromethamine salt) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost tromethamine salt is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost tromethamine salt plays a key role in the onset and progression of labour .

HY-176136

HNF4 agonist 1	Orphan Nuclear Receptor	Metabolic Disease
HNF4 agonist 1 is a HNF4 agonist. HNF4 agonist 1 activates HNF4α and HNF4γ with EC₅₀ values of 6 nM and 17 nM, respectively. HNF4 agonist 1 can be used in studies related to maturity-onset diabetes of the young type 1 (mody-1) .

HY-12956S

Dinoprost-d4 Prostaglandin F2a-d₄; PGF2α-d₄	Isotope-Labeled Compounds Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis	Endocrinology
Dinoprost-d₄ is the deuterium labeled Dinoprost. Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour .

HY-136528

RA-9	Deubiquitinase Apoptosis	Cancer
RA-9 is a potent and selective proteasome-associated deubiquitinating enzymes (DUBs) inhibitor with favorable toxicity profile and anticancer activity. RA-9 blocks ubiquitin-dependent protein degradation without impacting 20S proteasome proteolytic activity. RA-9 selectively induces onset of apoptosis in ovarian cancer cell lines and primary cultures derived from donors. RA-9 induces endoplasmic reticulum (ER)-stress responses in ovarian cancer cells .

HY-108506

Licarbazepine 1 Publications Verification BIA 2-005; GP 47779	Sodium Channel	Neurological Disease
Licarbazepine (BIA 2-005; GP 47779) is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects .

HY-112705

VU0529331	Potassium Channel	Neurological Disease Metabolic Disease
VU0529331 is a homomeric GIRK channel activator, with an EC₅₀ value of 5.1 μM for human GIRK2 and an EC₅₀ value of 22.3 μM for GIRK4. VU0529331 serves as a starting point for the development of non-GIRK1/X channel probes and also acts as a tool for studying homomeric GIRK channels. VU0529331 is applicable to research related to addiction, primary aldosteronism and delayed-onset obesity .

HY-W203683

Perfluorononanoic acid PFNA; Heptadecafluorononanoic acid	PPAR PERK	Metabolic Disease
Perfluorononanoic acid (PFNA) is an orally active PPARα activator. Perfluorononanoic acid activates PPARα-mediated gene expression, including upregulating target genes associated with lipid metabolism and triglyceride storage. Perfluorononanoic acid exhibits certain developmental and reproductive toxicity. Perfluorononanoic acid causes hepatomegaly in pregnant mice, induces high postnatal mortality in neonatal mice, and leads to dose-dependent delays in eye-opening time and puberty onset in mouse offspring .

HY-105077A

Nemifitide diTFA INN 00835 diTFA	5-HT Receptor	Neurological Disease
Nemifitide diTFA (INN 00835 diTFA) is a synthetic pentapeptide antidepressant with a potential for rapid onset of action . Nemifitide diTFA is a peptide analog of melanocyte-inhibiting factor (MIF) . Nemifitide diTFA can cross the blood-brain barrier .

HY-136066

Tauro-ω-muricholic acid sodium 1 Publications Verification TωMCA sodium	Endogenous Metabolite	Metabolic Disease
Tauro-ω-muricholic acid sodium (TωMCA sodium) is a bile acid released by the liver and an analog of tauro-α-muricholic acid. Tauro-ω-muricholic acid sodium is investigated as a potential marker in plasma for early-onset neonatal sepsis (EOS) and cholestasis studies

HY-101059

FGIN 1-27	GABA Receptor	Neurological Disease
FGIN 1-27, an indoleacetamide, is a specific peripheral benzodiazepine receptor (PBR) ligand with a K_i of 5.0 nM. FGIN 1-27 can penetrate the blood brain barrier (BBB). FGIN 1-27 inhibits the onset of Isoniazid-induced convulsions .

HY-108519

AS1892802	ROCK	Neurological Disease
AS1892802 is a potent, orally active, and highly selective inhibitor of ROCK. The onset of antinociceptive effect of AS1892802 is as fast as those of Tramadol and Diclofenac. AS1892802 did not induce gastric irritation or abnormal behavior. AS1892802 is an attractive analgesic profile for the research of severe osteoarthritis pain .

HY-A0014S1

Ramelteon-d3 TAK-375-d₃	Melatonin Receptor	Others
Ramelteon-d₃ (TAK-375-d₃) is a deuterium-labelled Ramelteon (HY-A0014). Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with K_i values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation.

HY-W014134

p-APMSF hydrochloride p-Amidinophenylmethylsulfonylfluoride hydrochloride	Ser/Thr Protease	Inflammation/Immunology
p-APMSF (p-Amidinophenylmethylsulfonylfluoride) hydrochloride is a serine protease and trypsin inhibitor with the characteristic of rapid onset of action. p-APMSF hydrochloride reduces the enzymatic hydrolysis of recombinant human G-CSF in rat pulmonary mucosa. Combined intratracheal treatment with p-APMSF hydrochloride and Laureth-9 significantly enhances its absorption efficiency in rat lungs. Following intranasal administration, p-APMSF hydrochloride does not increase the concentration of recombinant human G-CSF in rat plasma, nor does it alter the effect of G-CSF on inducing an increase in total white blood cell count .

HY-P10019

Pegsebrenatide NLY01	GCGR	Neurological Disease Inflammation/Immunology
Pegsebrenatide (NLY01) is a blood-brain barrier-penetrant GLP-1R agonist. Pegsebrenatide alleviates retinal inflammation and neuronal death secondary to ocular hypertension . Pegsebrenatide significantly delays onset and reduces disease severity in experimental autoimmune encephalomyelitis . Pegsebrenatide inhibits the formation of A1 reactive astrocytes in nerve cells and reduces the loss of retinal ganglion cells and dopaminergic neurons. Pegsebrenatide exerts neuroprotective effects in a mouse model of Parkinson's disease by directly preventing microglia-mediated conversion of astrocytes to the A1 neurotoxic phenotype. Pegsebrenatide can be used for research on glaucoma, Parkinson's disease, and multiple sclerosis .

HY-111817

ACT-451840	Parasite	Infection
ACT-451840 is an orally active, potent and low-toxicity compound, showing activity against sensitive and resistant plasmodium falciparum strains. ACT-451840 targets all asexual blood stages of the parasite, has a rapid onset of action. ACT-451840 behaves in a way similar to artemisinin derivatives, with very rapid onset of action and elimination of parasite. ACT-451840 can be used for the research of malarial .

HY-B0546AR

Procaine hydrochloride (Standard)	Reference Standards Histone Demethylase DNA/RNA Synthesis Bacterial	Neurological Disease Cancer
Procaine (hydrochloride) (Standard) is the analytical standard of Procaine (hydrochloride). This product is intended for research and analytical applications. Procaine hydrochloride is a DNA-demethylating agent. Procaine hydrochloride acts through multiple targets and has a slow onset and a short duration of action .

HY-145578

Linaprazan glurate X842	Drug Intermediate Proton Pump	Metabolic Disease
Linaprazan glurate (X842) is an orally atcive prodrug of Linaprazan (HY-100412) with a potent and prolonged inhibitory effect on gastric acid secretion. Linaprazan glurate is rapidly transformed by enzymatic cleavage into its active metabolite, linaprazan. Linaprazan glurate is a potassium-competitive acid blocker. Linaprazan glurate selectively inhibites acid formation from gastric H⁺/K⁺-ATPase in a potassium-dependent manner (IC₅₀ = 436.2 nM). Linaprazan glurate can be used for the studies of erosive esophagitis (EE) .

HY-111996

Kv3 activator-1	Potassium Channel	Neurological Disease Inflammation/Immunology
Kv3 activator-1 is a Kv3 family voltage-gated potassium channel activator. Kv3 activator-1 reverses mechanical hyperalgesia in rat models of neuropathic and inflammatory pain, with rapid onset and long-lasting, dose-related effects. Kv3 activator-1 can be used for the research of pain .

HY-Y0378S

D-Leucine-d10 (R)-Leucine-d₁₀	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease
D-Leucine-d₁₀ is the deuterium labeled D-Leucine. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .

HY-110174

NAB2	α-synuclein	Neurological Disease
NAB2 is a neuroprotectant that targets the small GTPase Rab1a. NAB2 selectively binds to the GDP-bound form of Rab1a and protects multiple cell types from α-synuclein toxicity by increasing Rab1a expression. Rab1a regulates ER-to-Golgi trafficking and mediates endosomal trafficking events of the E3 ubiquitin ligase Rsp5/Nedd4. NAB2 stimulates ubiquitination of related proteins in a Nedd4-dependent manner and rescues α-synuclein-associated trafficking defects associated with early-onset Parkinson's disease .

HY-113048A

Erythronic acid potassium 1 Publications Verification	Endogenous Metabolite	Metabolic Disease
Erythronic acid potassium is an endogenous metabolite of carbohydrates that can be used in the study of metabolism-related diseases. It plays a key role in the onset and improvement of hyperuricemia and is related to mitochondrial dysfunction in transaldolase deficiency .

HY-P2378

Neuromedin U-25 (human)	Endogenous Metabolite	Cardiovascular Disease
Neuromedin U-25 human is the active form of neuromedin U in human. Neuromedin U-25 human inhibits glucose-stimulated insulin secretion, which leads to early-onset obesity. Neuromedin U-25 serves as vasoconstrictor in human vascular beds .

HY-A0014S

Ramelteon-d5 TAK-375-d₅	Isotope-Labeled Compounds Melatonin Receptor	Neurological Disease Endocrinology Cancer
Ramelteon-d₅ is deuterium labeled Ramelteon. Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with K_i values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation .

HY-179505

OPN-9652	YAP	Cancer
OPN-9652 is a potent, orally active, and covalent TEAD inhibitor (MSTO-211H TEAD IC₅₀ = 0.005 µM) targeting the central palmitate binding pocket of TEADs. OPN-9652 reduces TEAD-dependent reporter activity and expression of TEAD targets (CTGF and CYR61). OPN-9652 resensitizes drug-tolerant SOX10 KO cells to BRAFi + MAPKi. OPN-9652 delays the onset of tumor resistance to BRAFi + MEKi from minimal residual disease (MRD) in a BRAF mutant A375 xenograft mouse model. OPN-9652 can be used for melanoma research .

HY-113048

Erythronic acid	Endogenous Metabolite	Metabolic Disease
Erythronic acid is an endogenous metabolite of carbohydrates that can be used in the study of metabolism-related diseases. It plays a key role in the onset and improvement of hyperuricemia and is related to mitochondrial dysfunction in transaldolase deficiency .

HY-112528

Glycerophospho-N-palmitoyl ethanolamine GP-NPEA	Endogenous Metabolite	Metabolic Disease
Glycerophospho-N-palmitoyl ethanolamine (GP-NPEA) is a metabolic precursor of palmitoyl ethanolamide PEA (HY-157829). Glycerophospho-N-palmitoyl ethanolamine decreases in the cortex of CUMS rats, which may be related to a disorder in the endocannabinoid system arising after the onset of depression .

HY-145486

1-Arachidonoyl-sn-glycerol 3-phosphate ammonium 20:4 Lyso PA	Liposome	Neurological Disease
1-Arachidonoyl-sn-glycerol 3-phosphate ammonium (20:4 Lyso PA) is a phospholipid and an LPA derived from arachidonic acid. The concentration of 1-Arachidonoyl-sn-glycerol 3-phosphate ammonium in plasma is significantly correlated with the age of onset of cocaine use and the duration of abstinence. 1-Arachidonoyl-sn-glycerol 3-phosphate ammonium can be used in the research of biomarkers for cocaine use disorder (CUD) .

HY-108506R

Licarbazepine (Standard) BIA 2-005 (Standard); GP 47779 (Standard)	Reference Standards Sodium Channel	Neurological Disease
Licarbazepine (Standard) is the analytical standard of Licarbazepine. This product is intended for research and analytical applications. Licarbazepine (BIA 2-005; GP 47779) is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects .

HY-178150

WEE1-IN-14	Wee1	Cancer
WEE1-IN-14 (Compound 14) is a selective WEE1 inhibitor (IC₅₀: 0.5 nM in L-RB-FEP calculations, 1.0 nM in ADP-Glo kinase assay). Inhibition of Wee1 in cancer cells disrupts the G2-M checkpoint, removes the regulatory controls on the cell cycle, and leads to early onset of mitotic failure followed by apoptosis of tumor cells. Therefore, WEE1-IN-14 is a useful tool for studying cancer biology .

HY-175184

LSD1-IN-44	Histone Demethylase	Infection
LSD1-IN-44 (Compound 19) is a LSD1 inhibitor with an IC₅₀ of 0.02  μM for LSD1-CoREST enzymatic complex. LSD1-IN-44 has significant antischistosomal activity against transformed schistosomula (NTS) and Schistosoma mansoni adult worms while showing a delayed onset of action towards juvenile forms. LSD1-IN-44 has no significant toxicity to human cells. LSD1-IN-44 can be used for schistosomiasis research .

HY-B1470S

Azaperone-d4 R-1929-d₄	Isotope-Labeled Compounds Dopamine Receptor Adrenergic Receptor	Neurological Disease
Azaperone-d₄ (R-1929-d₄) is the deuterium labeled Azaperone (HY-B1470). Azaperone is an antagonist of dopamine D2 receptor (Dopamine D2 Receptor) and α-adrenergic receptor (AR). Azaperone reduces vasomotor tone, mean arterial pressure, hematocrit, hemoglobin concentration, and etorphine-induced duration; induces transient tachycardia followed by bradycardia, splenic uptake of red blood cells, and sedation; alters animal behaviors; and produces sedation with distinct onset and duration in foals. Azaperone is used for sedation and tranquilization in various animals to reduce stress and aggressive behaviors, and serves as a preanesthetic agent.

HY-152014S

Stearoylcarnitine-d3-1 hydrochloride	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease
Stearoylcarnitine-d₃-1 (hydrochloride) is deuterium labeled Stearoylcarnitine. Stearoylcarnitine, a fatty ester lipid molecule, is a human endogenous metabolite. Stearoylcarnitine acts as a metabolomics biomarker for early-onset-preeclampsia and late-onset-preeclampsia .

HY-129423

Telmapitant	Neurokinin Receptor	Others
Telmapitant is an orally active NK1R antagonist. Telmapitant has antiemetic effect and can be used for the research of delayed onset emesis .

HY-19905

GW-597901	Adrenergic Receptor	Others
GW-597901 is a compound with bronchodilator activity that has a stronger bronchodilator effect than salbutamol in a human lung reperfusion model, but with a slightly slower onset of action.

Cat. No.	Product Name

HY-L103

Anti-Colorectal Cancer Compound Library

2,491 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 2,491 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

HY-L040

Anti-diabetic Compound Library

1,113 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 1,113 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.	Product Name	Target	Research Area

HY-109555

Insulin glulisine HMR 1964	Insulin Receptor	Metabolic Disease Inflammation/Immunology
Insulin glulisine (HMR 1964) is a rapid-acting insulin analog whose pharmacokinetic and pharmacodynamic properties mimic physiological insulin secretion in humans, with a rapid onset of action. Insulin glulisine controls hyperglycemia. Insulin glulisine is applicable to research related to type 1 diabetes and type 2 diabetes .

HY-105077A

Nemifitide diTFA INN 00835 diTFA	5-HT Receptor	Neurological Disease
Nemifitide diTFA (INN 00835 diTFA) is a synthetic pentapeptide antidepressant with a potential for rapid onset of action . Nemifitide diTFA is a peptide analog of melanocyte-inhibiting factor (MIF) . Nemifitide diTFA can cross the blood-brain barrier .

HY-P10019

Pegsebrenatide NLY01	GCGR	Neurological Disease Inflammation/Immunology
Pegsebrenatide (NLY01) is a blood-brain barrier-penetrant GLP-1R agonist. Pegsebrenatide alleviates retinal inflammation and neuronal death secondary to ocular hypertension . Pegsebrenatide significantly delays onset and reduces disease severity in experimental autoimmune encephalomyelitis . Pegsebrenatide inhibits the formation of A1 reactive astrocytes in nerve cells and reduces the loss of retinal ganglion cells and dopaminergic neurons. Pegsebrenatide exerts neuroprotective effects in a mouse model of Parkinson's disease by directly preventing microglia-mediated conversion of astrocytes to the A1 neurotoxic phenotype. Pegsebrenatide can be used for research on glaucoma, Parkinson's disease, and multiple sclerosis .

HY-P2378

Neuromedin U-25 (human)	Endogenous Metabolite	Cardiovascular Disease
Neuromedin U-25 human is the active form of neuromedin U in human. Neuromedin U-25 human inhibits glucose-stimulated insulin secretion, which leads to early-onset obesity. Neuromedin U-25 serves as vasoconstrictor in human vascular beds .

HY-P5451

PLP (178-191)	Peptides	Others
PLP (178-191) is a biological active peptide. (This is amino acids 178 to 191 fragment of the proteolipid protein (PLP), an immunodominant encephalitogenic epitope in SJL mice, one of two major encephalitogenic epitopes. PLP peptide 178 to 191 was compared with another encephalitogenic peptide, 139 to 151. The day of onset of disease induced by PLP 178 to 191 was earlier, but the incidence, severity, and histologic features were indistinguishable.)

HY-105077AR

Nemifitide diTFA (Standard) INN 00835 diTFA (Standard)	Reference Standards 5-HT Receptor	Neurological Disease
Nemifitide diTFA (Standard) is the analytical standard of Nemifitide diTFA (HY-105077A). This product is intended for research and analytical applications. Nemifitide diTFA (INN 00835 diTFA) is a synthetic pentapeptide antidepressant with a potential for rapid onset of action . Nemifitide diTFA is a peptide analog of melanocyte-inhibiting factor (MIF) . Nemifitide diTFA can cross the blood-brain barrier .

Cat. No.	Product Name	Target	Research Area	Image

HY-108786

Asfotase alfa ENB-0040	Phosphatase	Metabolic Disease
Asfotase alfa (ENB-0040) is a bone-targeted genetically engineered glycoprotein. Asfotase alfa increases the survival rate, bone mineralization and bone length and prevents mineralization defects of the feet, rib cage, lower limbs, jaw bones in Akp2 ^/ knockout mice. Asfotase alfa can be used for the research of perinatal, infantile, and juvenile-onset hypophosphatasia (HPP) .

HY-P990043

Iluzanebart VGL101	Ser/Thr Kinase TREM receptor	Inflammation/Immunology
Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP) .

HY-P99803

Clervonafusp alfa VAL-1221	Glycosidase	Others
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .

HY-P992393

JMT203	TGF-β Receptor	Cancer
JMT203 is a monoclonal antibody against GFRAL and a body weight gain inducer. JMT203 induces early-onset, sustained and progressive body weight gain in cancer cachexia. JMT203 can be used for research related to cancer cachexia .

HY-P992380

IBC-Ab002	PD-1/PD-L1	Neurological Disease
IBC-Ab002 is a humanized anti-PD-L1 monoclonal antibody with a modified Fc backbone that shortens its circulating half-life. IBC-Ab002 inhibits PD-L1, triggers immune responses by blocking the PD-1/PD-L1 pathway, promotes the recruitment of myeloid-derived immune cells to the brain, enhances the clearance of toxic substances in the brain, improves neuronal function and reduces inflammation. IBC-Ab002 reduces the risk of accelerated onset of autoimmune diabetes in susceptible mice. IBC-Ab002 can be used in research related to Alzheimer's disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-12956

Dinoprost Maximum Cited Publications 9 Publications Verification Prostaglandin F2α; PGF2α	Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis
Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour .

HY-Y0378

D-Leucine (R)-Leucine	Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Endogenous Metabolite
D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .

HY-12956A

Dinoprost tromethamine salt Maximum Cited Publications 9 Publications Verification Prostaglandin F2α tromethamine salt; PGF2α THAM; Prostaglandin F2α THAM	Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis
Dinoprost tromethamine salt (Prostaglandin F2α tromethamine salt) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost tromethamine salt is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost tromethamine salt plays a key role in the onset and progression of labour .

HY-126359

1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine SLPC; 18:0-18:2 PC	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Lipid Source Classification	Endogenous Metabolite
1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine (SLPC; 18:0-18:2 PC) is an endogenous phospholipid marker molecule in the glycerophospholipid metabolic pathway. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine is a core component of the phospholipid bilayer of biological membranes and a key responsive lipid for radiation injury and cardiometabolic diseases. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine constitutes the phospholipid bilayers of cell membranes and high-density lipoprotein (HDL), and regulates the core activity of lipoprotein functional homeostasis. The content of 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine in mouse serum shows a significant dose-dependent decrease with increasing ionizing radiation dose, and its level in human HDL also decreases significantly in metabolic syndrome. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can serve as a biological dosimeter marker for ionizing radiation injury, and is used for rapid and accurate assessment of radiation absorbed dose in exposed individuals. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can also act as a lipidomics research target for cardiometabolic diseases such as lipid metabolic syndrome and early-onset coronary heart disease .

HY-113048A

Erythronic acid potassium 1 Publications Verification	Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Saccharides Monosaccharides Source Classification	Endogenous Metabolite
Erythronic acid potassium is an endogenous metabolite of carbohydrates that can be used in the study of metabolism-related diseases. It plays a key role in the onset and improvement of hyperuricemia and is related to mitochondrial dysfunction in transaldolase deficiency .

HY-113048

Erythronic acid	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Saccharides Monosaccharides Source Classification	Endogenous Metabolite
Erythronic acid is an endogenous metabolite of carbohydrates that can be used in the study of metabolism-related diseases. It plays a key role in the onset and improvement of hyperuricemia and is related to mitochondrial dysfunction in transaldolase deficiency .

HY-113246

15-keto-Prostaglandin F2a 15-keto-PGF2α	Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Prostaglandin Receptor Endogenous Metabolite
15-keto-Prostaglandin F2α (15-keto-PGF2α) is a metabolite of Prostaglandin F2α. Prostaglandin F2α. Prostaglandin F2α is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist and plays a key role in the onset and progression of labour .

HY-12956R

Dinoprost (Standard) Prostaglandin F2α (Standard); PGF2α (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis
Dinoprost (Standard) is the analytical standard of Dinoprost. This product is intended for research and analytical applications. Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour .

HY-12956AR

Dinoprost tromethamine salt (Standard) Prostaglandin F2α tromethamine salt (Standard); PGF2α THAM (Standard); Prostaglandin F2α THAM (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Prostaglandin Receptor Endogenous Metabolite Autophagy Apoptosis
Dinoprost (tromethamine salt) (Standard) is the analytical standard of Dinoprost (tromethamine salt). This product is intended for research and analytical applications. Dinoprost tromethamine salt (Prostaglandin F2α tromethamine salt) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost tromethamine salt is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost tromethamine salt plays a key role in the onset and progression of labour .

HY-Y0378R

D-Leucine (Standard) (R)-Leucine (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
D-Leucine (Standard) is the analytical standard of D-Leucine. This product is intended for research and analytical applications. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .

Cat. No.	Product Name	Chemical Structure

HY-12956S

Dinoprost-d4
Dinoprost-d₄ is the deuterium labeled Dinoprost. Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour .

HY-A0014S1

Ramelteon-d3

Ramelteon-d₃ (TAK-375-d₃) is a deuterium-labelled Ramelteon (HY-A0014). Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with K_i values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation.

HY-Y0378S

D-Leucine-d10
D-Leucine-d₁₀ is the deuterium labeled D-Leucine. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .

HY-A0014S

Ramelteon-d5

Ramelteon-d₅ is deuterium labeled Ramelteon. Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with K_i values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation .

HY-B1470S

Azaperone-d4

Azaperone-d₄ (R-1929-d₄) is the deuterium labeled Azaperone (HY-B1470). Azaperone is an antagonist of dopamine D2 receptor (Dopamine D2 Receptor) and α-adrenergic receptor (AR). Azaperone reduces vasomotor tone, mean arterial pressure, hematocrit, hemoglobin concentration, and etorphine-induced duration; induces transient tachycardia followed by bradycardia, splenic uptake of red blood cells, and sedation; alters animal behaviors; and produces sedation with distinct onset and duration in foals. Azaperone is used for sedation and tranquilization in various animals to reduce stress and aggressive behaviors, and serves as a preanesthetic agent.

HY-152014S

Stearoylcarnitine-d3-1 hydrochloride
Stearoylcarnitine-d₃-1 (hydrochloride) is deuterium labeled Stearoylcarnitine. Stearoylcarnitine, a fatty ester lipid molecule, is a human endogenous metabolite. Stearoylcarnitine acts as a metabolomics biomarker for early-onset-preeclampsia and late-onset-preeclampsia .

HY-B0546AS

Procaine-d4 hydrochloride
Procaine-d₄ (hydrochloride) is the deuterium labeled Procaine hydrochloride. Procaine hydrochloride is a DNA-demethylating agent. Procaine hydrochloride acts through multiple targets and has a slow onset and a short duration of action .

HY-W704876

Procaine hydrochloride-d4
Procaine hydrochloride-d₄ is the deuterium labeled Procaine hydrochloride (HY-B0546A). Procaine hydrochloride is a DNA-demethylating agent. Procaine hydrochloride acts through multiple targets and has a slow onset and a short duration of action .

HY-12956S1

Dinoprost-d9
Dinoprost-d₉ is the deuterium labeled Dinoprost. Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour .

HY-12956S2

Dinoprost-13C5
Dinoprost- ¹³C₅ is ¹³C labeled Dinoprost (HY-12956). Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86790

	BRCA2 Antibody (YA6483) BRCA 2 antibody; BRCA1/BRCA2 containing complex subunit 2 antibody; Brca2 antibody; BRCA2, DNA repair associated antibody; BRCA2_HUMAN antibody; BRCC 2 antibody; BRCC2 antibody; Breast and ovarian cancer susceptibility gene early onset antibody; breast and ovarian cancer susceptibility protein 2 antibody; Breast cancer 2 early onset antibody; BRCA 2 antibody; BRCA1/BRCA2 containing complex subunit 2 antibody; Brca2 antibody; BRCA2, DNA repair associated antibody; BRCA2_HUMAN antibody; BRCC 2 antibody; BRCC2 antibody; Breast and ovarian cancer susceptibility gene early onset antibody; breast and ovarian cancer susceptibility protein 2 antibody; Breast cancer 2 early onset antibody; Breast Cancer 2 tumor suppressor antibody; Breast cancer susceptibility protein BRCA2 antibody; Breast cancer type 2 susceptibility protein antibody; BROVCA2 antibody; FACD antibody; FAD 1 antibody; FAD antibody; FAD1 antibody; FANCB antibody; FANCD 1 antibody; FANCD antibody; FANCD1 antibody; FANCD1 gene antibody; Fanconi anemia complementation group D1 antibody; Fanconi anemia group D1 protein antibody; GLM3 antibody; mutant BRCA2 antibody; OTTHUMP00000018803 antibody; OTTHUMP00000042401 antibody; PNCA2 antibody; XRCC11 antibody;	WB, FC	Human
	BRCA2 Antibody (YA6483) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BRCA2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-175185

MC3935		Alkynes
MC3935 is a LSD1 inhibitor with an IC₅₀ of 0.52  μM for LSD1-CoREST enzymatic complex. MC3935 has significant antischistosomal activity against transformed schistosomula (NTS) and Schistosoma mansoni adult worms while showing a delayed onset of action towards juvenile forms. MC3935 has no significant toxicity to human cells. MC3935 can be used for schistosomiasis research .

HY-181033

(M)-AVI-4773		Alkynes
(M)-AVI-4773 is an orally active, blood-brain barrier permeable coronaviruses M ^Pro inhibitor with an IC₅₀ of 2.5 nM aginst SARS-CoV-2 M ^Pro. (M)-AVI-4773 produces a rapid onset antiviral effect in mouse models of MERS-CoV and SARS-CoV-2 infection .

Cat. No.	Product Name		Classification